HWHG(SH:600079) Xin Lang Cai Jing·2025-09-10 03:05Core Viewpoint - The stock price of Renfu Pharmaceutical has shown a slight decline this year, with a recent drop of 2.04% on September 10, 2023, indicating potential market volatility and investor sentiment concerns [1][2]. Company Overview - Renfu Pharmaceutical Group Co., Ltd. was established on March 30, 1993, and went public on June 6, 1997. The company is located in Wuhan, Hubei Province, and its main business includes research, production, sales, and technical services related to pharmaceuticals, medical devices, and reproductive health [2]. - The revenue composition of the company is as follows: pharmaceuticals and others account for 81.96%, medical devices for 17.85%, and other (supplementary) for 0.19% [2]. Financial Performance - For the first half of 2025, Renfu Pharmaceutical reported a revenue of 12.064 billion yuan, a year-on-year decrease of 6.20%. However, the net profit attributable to shareholders increased by 3.92% to 1.155 billion yuan [2]. - The company has distributed a total of 3.113 billion yuan in dividends since its A-share listing, with 1.779 billion yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Renfu Pharmaceutical was 50,100, an increase of 0.55% from the previous period. The average circulating shares per person decreased by 0.54% to 30,825 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 43.5739 million shares, a decrease of 9.1957 million shares from the previous period [3].